For most protease inhibitors, such as leupeptin and aprotinin, doubling the concentration typically does not negatively impact the assay. However, with specific inhibitors like the DPPIV inhibitor referenced, higher concentrations can interfere with the assay, which is why additional instructions are provided. Other DPPIV inhibitors, such as Diprotin A, do not interfere at any concentration but are not as effective.
Über diesen Artikel
Fortfahren mit
Speziesreaktivität
human
Hersteller/Markenname
Milliplex®
assay range
accuracy: 101%
(Glucagon)
accuracy: 102%
(Leptin)
accuracy: 103%
(GIP)
accuracy: 103%
(GLP-1 (Total))
accuracy: 105%
(Ghrelin (Active))
accuracy: 106%
(MCP-1)
accuracy: 97%
(TNFα)
accuracy: 99%
(C-Peptide)
sensitivity: 0.5 pg/mL
(MinDC+2SD; TNF?)
sensitivity: 1.1 pg/mL
(MinDC+2SD; GIP)
sensitivity: 13 pg/mL
(MinDC+2SD; IL-6)
sensitivity: 14 pg/mL
(MinDC+2SD; Ghrelin (Active))
sensitivity: 14 pg/mL
(MinDC+2SD; MCP-1)
sensitivity: 146 pg/mL
(MinDC+2SD; PYY)
sensitivity: 15 pg/mL
(MinDC+2SD; Amylin (Total))
sensitivity: 16 pg/mL
(MinDC+2SD; C-Peptide)
sensitivity: 16 pg/mL
(MinDC+2SD; Glucagon)
sensitivity: 160 pg/mL
(MinDC+2SD; Insulin)
sensitivity: 2.4 pg/mL
(MinDC+2SD; GLP-1 (Active))
sensitivity: 2.9 pg/mL
(MinDC+2SD; PP)
sensitivity: 28 pg/mL
(MinDC+2SD; Amylin (Active))
sensitivity: 64 pg/mL
(MinDC+2SD; Leptin)
sensitivity: 7.3 pg/mL
(MinDC+2SD; GLP-1 (Total))
standard curve range: 0.69-500 pg/mL
(TNFα)
standard curve range: 1.4-1,000 pg/mL
(GIP)
standard curve range: 13.7-10,000 pg/mL
(Amylin (Active))
standard curve range: 13.7-10,000 pg/mL
(Amylin (Total))
standard curve range: 13.7-10,000 pg/mL
(Ghrelin (Active))
standard curve range: 13.7-10,000 pg/mL
(Glucagon)
standard curve range: 13.7-10,000 pg/mL
(IL-6)
standard curve range: 13.7-10,000 pg/mL
(MCP-1)
standard curve range: 13.7-10,000 pg/mL
(PYY)
standard curve range: 137-100,000 pg/mL
(Insulin)
standard curve range: 137-100,000 pg/mL
(Leptin)
standard curve range: 2.7-2,000 pg/mL
(GLP-1 (Active))
standard curve range: 2.7-2,000 pg/mL
(GLP-1 (Total))
standard curve range: 2.7-2,000 pg/mL
(PP)
standard curve range: 27.4-20,000 pg/mL
(C-Peptide)
inter-assay cv: <15%
intra-assay cv: <10%
(C-Peptide)
inter-assay cv: <15%
intra-assay cv: <10%
(GIP)
inter-assay cv: <15%
intra-assay cv: <10%
(GLP-1 (Active))
inter-assay cv: <15%
intra-assay cv: <10%
(GLP-1 (Total))
inter-assay cv: <15%
intra-assay cv: <10%
(Ghrelin (Active))
inter-assay cv: <15%
intra-assay cv: <10%
(Glucagon)
inter-assay cv: <15%
intra-assay cv: <10%
(IL-6)
inter-assay cv: <15%
intra-assay cv: <10%
(Insulin)
inter-assay cv: <15%
intra-assay cv: <10%
(Leptin)
inter-assay cv: <15%
intra-assay cv: <10%
(MCP-1)
inter-assay cv: <15%
intra-assay cv: <10%
(PP)
inter-assay cv: <15%
intra-assay cv: <10%
(PYY)
inter-assay cv: <15%
intra-assay cv: <10%
(TNFα)
inter-assay cv: <20%
intra-assay cv: <10%
(Amylin (Active))
inter-assay cv: <20%
intra-assay cv: <10%
(Amylin (Total))
Methode(n)
multiplexing: suitable
Nachweisverfahren
fluorometric (Luminex xMAP)
Versandbedingung
wet ice
Allgemeine Beschreibung
The MILLIPLEX® Human Metabolic Hormone Panel is a 15 analyte, 13-plex kit to be used for the simultaneous quantification of any or all of the following analytes in serum, plasma and cell/tissue culture samples: Amylin (Active) or Amylin (Total), C-Peptide, Ghrelin (Active), GIP, GLP-1 (Active) or GLP-1 (Total), Glucagon, IL-6, Insulin, Leptin, MCP-1, PP, PYY, TNFα. This kit uses a 96-well format, contains a lyophilized standard cocktail, two internal assay quality controls and can measure up to 38 samples in duplicate.
The Luminex® xMAP® platform uses a magnetic bead immunoassay format for ideal speed and sensitivity to quantitate multiple analytes simultaneously, dramatically improving productivity while conserving valuable sample volume.
Panel Type: Metabolism
Anwendung
- Analytes: Amylin (Active), Amylin (Total), C-Peptide, Ghrelin (Active), GIP (Total), GLP-1 (Active), GLP-1 (Total), Glucagon, IL-6, Insulin, Leptin, MCP-1 (CCL2), Pancreatic Polypeptide (PP), PYY (Total), TNF-α
- NOTE: The following analytes cannot be assayed simultaneously: Amylin (Active) & Amylin (Total); GLP-1 (Active) & GLP-1 (Total).
- Recommended Sample Type: Human serum, plasma, and cell/tissue culture supernatants or lysates
- Recommended Sample Dilution: 25 μL per well of undiluted serum or plasma; cell/tissue culture samples may be used undiluted or diluted with an appropriate control medium NOTE: The following analytes require the addition of protease inhibitors to serum or plasma samples (see sample collection and storage section in the protocol for details): GLP-1 (DPPIV inhibitor); Amylin (protease inhibitor cocktail); Glucagon (Aprotinin); Ghrelin (Active) (serine protease inhibitor).
- Assay Run Time: Overnight (16-18 hours) at 2-8°C
- Research Category: Metabolism
- Research Subcategory: Metabolic Disorders
Leistungsmerkmale und Vorteile
Sonstige Hinweise
Rechtliche Hinweise
Signalwort
Danger
Gefahreneinstufungen
Acute Tox. 3 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Irrit. 2 - Skin Sens. 1
Lagerklassenschlüssel
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
Analysenzertifikate (COA)
Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.
Besitzen Sie dieses Produkt bereits?
In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.
-
How much protease inhibitor should be added when using only the plasma instead of the entire blood sample?
1 answer-
Helpful?
-
-
Could you please provide information on the epitopes targeted by the antibodies HMHE-1034-2 and HMHE-1034-1, which are used in the MILLIPLEX MAP Human Metabolic Hormone Magnetic Bead Panel - Metabolism Multiplex Assay? Specifically, I would like to know if the anti-GLP-1 antibody would be able to bind to a commercial drug such as semaglutide.
1 answer-
This antidiabetic medication for the treatment of type 2 diabetes and as anti-obesity medication for long-term weight management is known as Semaglutide. It is sold under the brand names Ozempic, Wegovy, and Rybelsus. Semaglutide was developed by Novo Nordisk in 2012. It is a GLP-1 receptor agonist, meaning that it mimics the action of the human incretin glucagon-like peptide-1 (GLP-1), thereby increasing insulin secretion and increasing blood sugar disposal and improving glycemic control.
Helpful?
-
Active Filters
Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..
Setzen Sie sich mit dem technischen Dienst in Verbindung
